Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Basal Cell Cancer
Data on basal cell cancer discussed by F.I. Ezughah and colleagues
June 10th, 2008
According to a study from Scotland, "This study was designed to compare the safety and efficacy of two cycled dosing regimens of imiquimod 5% cream for treatment of superficial basal cell carcinoma (sBCC). Patients (n=32) were randomized to receive one of two treatment regimens: 8 weeks of treatment with once-daily dosing for alternate weeks (RI) and 5 weeks of once-daily dosing with a 1-week interval in the middle of the course (R2)." "Efficacy measures were tumour clearance at weeks 19 and 52 and measures of patients' acceptability. Data from 30 patients (13 females), 14 on RI and 16 on R2, were analysed. The results revealed an initial clearance rate of 64% at week...
Source: Cancer Weekly (2008-06-10)
|
